Influenza Vaccine Response
Conditions
Keywords
Vaccine Efficacy, Elderly Immunity, Fatty Acid Supplementation, Gut Microbiota, Randomized Controlled Trial
Brief summary
The aim of this clinical trial is to explore the efficacy of fatty acid and bile acid based supplements on enhancing influenza vaccine immune response in adults aged 60-70 years. The objectives of this study are: 1. To explore the efficacy of fatty acid and bile acid based supplements on enhancing flu vaccine immune response. 2. To evaluate the safety of fatty acid and bile acid use in elders. 3. To explore the potential role of microbiota in regulating immune response. This study will conduct a randomized clinical trial to compare the efficacy of fatty acid / bile acid (Tauro Ursodesoxy Cholic Acid, TUDCA)supplements on enhancing vaccine immune response. The antibody's titer and safety indicators after influenza vaccination will be evaluated. Study process are: 1. Participants will be required to intake the assigned supplement or placebo daily for 25 days; 2. Receive a influenza vaccine on day 4; 3. Provide blood samples three times and stool samples twice at base line and endpoint respectively; 4. The antibody's titer and safety indicators will be analyzed and compared among groups. This study aims to establish a theoretical foundation for utilizing nutritional strategies to enhance vaccine-induced immune responses and to provide a scientific framework for developing oral vaccine boosters.
Detailed description
Influenza virus infection presents a significant global health challenge, particularly threatening the elderly population due to immunosenescence. The immune response to influenza vaccination involves a complex series of events: after vaccination, hemagglutination inhibition antibody titers peak around day 14, accompanied by the production of neutralizing antibodies and other specific antibodies. This immune response gradually stabilizes to a post-response baseline level as immune memory establishes. The age-related decline in immune function manifests through multiple mechanisms,including: reduced production of naive T cells; decreased diversity of T cell repertoire; compromised B cell function, altered cytokine production profiles which all diminished vaccine response efficacy. Recent advances in immunometabolism have revealed the crucial role of specific fatty acids in immune system modulation. Our preliminary explorations found that，short-term Arachidonic Acid（AA）intervention could significantly reduce the time required for antibody production and enhance its levels following rabies vaccination. We also noticed that the serum Tauro Ursodesoxy Cholic Acid (TUDCA) was elevated in the intervention group. However, the related mechanism is still not clear. The theoretical framework integrates nutritional immunology with classical vaccinology, focusing on the metabolic interaction between dietary fatty acids and immune cell function. This approach is particularly relevant for the elderly population, where reduced vaccine responsiveness due to immunosenescence presents a significant challenge in achieving optimal vaccine protection.
Interventions
DIETARY_SUPPLEMENTARA (Arachidonic Acid) Supplementation
Oral ARA (Arachidonic Acid) dietary supplement capsules, dosage 1000 mg/person/day. Capsule composition includes: C14:0 (0.15%), C16:0 (6.08%), C16:1 (0.15%), C18:0 (4.57%), C18:1 (19.65%), C18:2 (38.46%), C18:3 (0.87%), C20:0 (0.50%), C20:3 (2.00%), C20:4 (18.66%), C22:0 (1.81%), C24:0 (4.05%). Maintain original lifestyle during intervention, Day 0-Day 2 as adaptation period, receive quadrivalent influenza vaccine on Day 3, continue supplementation until Day 24.
Oral Double Wood brand TUDCA (Tauroursodeoxycholic Acid) dietary supplement capsules, dosage 1000 mg/person/day. Capsules primarily contain TUDCA, with 500 mg per serving (two capsules), other ingredients include gelatin and rice powder. Maintain original lifestyle during intervention, Day 0-Day 2 as adaptation period, receive quadrivalent influenza vaccine on Day 3, continue supplementation until Day 24.
DIETARY_SUPPLEMENTPlacebo Supplementation
Oral placebo capsules identical in appearance and smell, dosage 1000 mg/person/day. Placebo capsule composition includes: C14:0 (0.09%), C16:0 (6.12%), C16:1 (0.03%), C18:0 (3.50%), C18:1 (28.06%), C18:2 (59.40%), C20:0 (0.27%), C22:0 (0.76%), C24:0 (0.26%). Maintain original lifestyle during intervention, Day 0-Day 2 as adaptation period, receive quadrivalent influenza vaccine on Day 3, continue taking placebo until Day 24.
BIOLOGICALShanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine
Administer Shanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine, produced by Shanghai Biological Products Research Institute Co., Ltd. , specification 0.5ml/dose, containing 15.0 μg hemagglutinin (for each influenza virus strain), suitable for intramuscular injection in individuals 6 months and older. Administer one dose to all study participants on Day 3. Closely observe and record any potential adverse reactions after vaccination.
Sponsors
Second Affiliated Hospital of Bengbu Medical College
Tsinghua University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
All study supplements are identical in appearance and packaging to maintain blinding.
Intervention model description
Forty-five adults aged 60-70 years are randomly assigned in equal numbers (n=15 per group) to three parallel groups: two intervention groups receiving different supplements(arachidonic acid and TUDCA) and one control group receiving placebo. The intervention period lasts 25 days, from Day 0 to Day 24. Triple-blinding is implemented to ensure that both participants and investigators are unaware of group assignments.
Eligibility
Sex/Gender
ALL
Age
60 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age 60-70 years old 2. Body Mass Index (BMI) 18.5-26.9 kg/m² 3. No influenza vaccination in the past year 4. Able to understand and sign the informed consent form, and capable of completing the full follow-up process
Exclusion criteria
1. Severe lipid metabolism disorders 2. Use of lipid-lowering medications, weight loss drugs, or insulin within the past three months 3. Vaccination with other vaccines within the past three months 4. Use of probiotics or prebiotics within the past three months 5. Use of steroids, immunosuppressants, or other hormonal medications within the past year 6. Immunodeficiency diseases 7. Severe vaccine allergy history 8. Liver or kidney metabolic disorders 9. Occurrence of fever, common cold, severe diarrhea, or other diseases within the past month 10. Poorly controlled chronic diseases (such as blood pressure, blood sugar) 11. Intake of influenza antiviral drugs within the past two weeks 12. Cognitive function impairment 13. Planning to undergo surgery in the near future
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Specific Antibody Levels and Neutralizing Antibody Responses to Influenza Vaccine | Day 13 and Day 24 | By detecting serum neutralizing and specific antibody levels on Day 13 and Day 24, evaluate the impact of different dietary supplements on influenza vaccine immune responses in elderly individuals. Focus primarily on changes in antibody titers to determine whether dietary supplementation can enhance vaccine immunogenicity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Inflammatory Markers | Day 0 and Day 24 | Measure serum levels of inflammatory factors such as IL-1, IL-2, IL-6, IL-8, IL-10, IL-17 to assess the potential modulatory effect of dietary supplementation on inflammatory responses. |
| Gut Microbiota Composition Changes | Day 0 and Day 24 | Analyze intestinal microbiota structure and metabolomics changes through fecal samples to explore the impact of dietary supplementation on gut microecology, including: 1. Alpha diversity analysis (Shannon index, Chao1 index, observed species) 2. Beta diversity analysis (UniFrac distance, Bray-Curtis dissimilarity) 3. Microbial species composition and relative abundance changes 4. Key microbiota (such as Bacteroidetes, Actinobacteria) abundance analysis 5. Metabolic pathway changes, including KEGG functional pathway prediction and microbiota-related immune metabolic pathways |
| Metabolomics Analysis | Day 0, Day 13 and Day 24 | Perform non-targeted metabolomics detection to evaluate the impact of dietary supplementation on human metabolic levels, including lipid profiles, liver and kidney function indicators. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Dietary Intake Assessment | Day 0 and Day 24 | Record dietary intake patterns of study subjects through 24-hour dietary recall and FFQ surveys to control nutritional factors that might influence results. |
| Coagulation Function and Thrombosis Risk Assessment | Day 0 and Day 24 | Assess the impact of dietary supplements on blood coagulation function by detecting coagulation time and related coagulation indicators, and exclude the risks of coagulation disorders and thrombosis. Focus on changes in coagulation time, platelet count, and coagulation factors. |
| Safety Assessment | Throughout the entire study period (Day 0-Day 24) | Record and analyze adverse reactions during the intervention, including clinical symptoms, blood routine, and biochemical indicators to assess the safety of dietary supplements. |
Countries
China
Contacts
Primary ContactAi Zhao, Doctor
Outcome results
None listed